- Home
- CMPS vs ADCT Comparison
CMPS vs ADCT Comparison
Compare CMPS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- ADCT
- Stock Information
- Founded
- CMPS 2020
- ADCT 2011
- Country
- CMPS United Kingdom
- ADCT Switzerland
- Employees
- CMPS N/A
- ADCT N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- ADCT Health Care
- Exchange
- CMPS Nasdaq
- ADCT Nasdaq
- Market Cap
- CMPS 280.2M
- ADCT 224.3M
- IPO Year
- CMPS 2020
- ADCT 2020
- Fundamental
- Price
- CMPS $4.14
- ADCT $2.12
- Analyst Decision
- CMPS Strong Buy
- ADCT Strong Buy
- Analyst Count
- CMPS 6
- ADCT 5
- Target Price
- CMPS $33.60
- ADCT $8.00
- AVG Volume (30 Days)
- CMPS 663.3K
- ADCT 1.7M
- Earning Date
- CMPS 10-31-2024
- ADCT 11-07-2024
- Dividend Yield
- CMPS N/A
- ADCT N/A
- EPS Growth
- CMPS N/A
- ADCT N/A
- EPS
- CMPS N/A
- ADCT N/A
- Revenue
- CMPS N/A
- ADCT $70,717,000.00
- Revenue This Year
- CMPS N/A
- ADCT $6.58
- Revenue Next Year
- CMPS N/A
- ADCT $11.78
- P/E Ratio
- CMPS N/A
- ADCT N/A
- Revenue Growth
- CMPS N/A
- ADCT N/A
- 52 Week Low
- CMPS $3.86
- ADCT $1.45
- 52 Week High
- CMPS $12.75
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- CMPS 41.43
- ADCT 46.65
- Support Level
- CMPS $3.86
- ADCT $1.93
- Resistance Level
- CMPS $4.20
- ADCT $2.18
- Average True Range (ATR)
- CMPS 0.29
- ADCT 0.41
- MACD
- CMPS 0.02
- ADCT -0.01
- Stochastic Oscillator
- CMPS 27.01
- ADCT 18.64
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.